BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Komanduri S, Muthusamy VR, Wani S. Controversies in Endoscopic Eradication Therapy for Barrett's Esophagus. Gastroenterology 2018;154:1861-1875.e1. [PMID: 29458152 DOI: 10.1053/j.gastro.2017.12.045] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Tustumi F, de Moura DTH, Waisberg J, Herbella FAM. Editorial: Premalignant conditions in the esophagus and stomach. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1091911] [Reference Citation Analysis]
2 Wani S, Souza RF, Durkalski VL, Serrano J, Hamilton F, Shaheen NJ; SURVENT Trial Consortium. Multicenter Randomized Controlled Trial of Surveillance Versus Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia: The SURVENT Trial: Study Rationale, Methodology, Innovation, and Implications. Gastroenterology 2022;163:556-562.e4. [PMID: 35679951 DOI: 10.1053/j.gastro.2022.05.051] [Reference Citation Analysis]
3 Wong CK, Joseph K, Turner SR. Treatment Options for Patients With Persistent Disease After Initial Endotherapy for Esophageal Neoplasia. Foregut 2022;2:123-131. [DOI: 10.1177/26345161221115360] [Reference Citation Analysis]
4 Choi WT, Lauwers GY, Montgomery EA. Utility of ancillary studies in the diagnosis and risk assessment of Barrett's esophagus and dysplasia. Mod Pathol 2022. [PMID: 35260826 DOI: 10.1038/s41379-022-01056-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Condon A, Muthusamy VR. The evolution of endoscopic therapy for Barrett's esophagus. Ther Adv Gastrointest Endosc 2021;14:26317745211051834. [PMID: 34708204 DOI: 10.1177/26317745211051834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Panda A, Shin MR, Cheng C, Bajpai M. Barrett's Epithelium to Esophageal Adenocarcinoma: Is There a "Point of No Return"? Front Genet 2021;12:706706. [PMID: 34603373 DOI: 10.3389/fgene.2021.706706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Elias PS, Spechler SJ. Barrett's Esophagus. The Esophagus 2021. [DOI: 10.1002/9781119599692.ch29] [Reference Citation Analysis]
8 Bowman CJ, Zhang R, Balitzer D, Wang D, Rabinovitch PS, Kővári BP, Mattis AN, Kakar S, Lauwers GY, Choi WT. Persistent or recurrent Barrett's neoplasia after an endoscopic therapy session is associated with DNA content abnormality and can be detected by DNA flow cytometric analysis of paraffin-embedded tissue. Mod Pathol 2021. [PMID: 34108638 DOI: 10.1038/s41379-021-00832-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Rouphael C, Anil Kumar M, Sanaka MR, Thota PN. Indications, contraindications and limitations of endoscopic therapy for Barrett's esophagus and early esophageal adenocarcinoma. Therap Adv Gastroenterol 2020;13:1756284820924209. [PMID: 32523628 DOI: 10.1177/1756284820924209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Porter RJ, Murray GI, Brice DP, Petty RD, McLean MH. Novel biomarkers for risk stratification of Barrett's oesophagus associated neoplastic progression-epithelial HMGB1 expression and stromal lymphocytic phenotype. Br J Cancer 2020;122:545-54. [PMID: 31831860 DOI: 10.1038/s41416-019-0685-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
11 Cholapranee A, Trindade AJ. Challenges in Endoscopic Therapy of Dysplastic Barrett's Esophagus. Curr Treat Options Gastroenterol 2019;17:32-47. [PMID: 30663018 DOI: 10.1007/s11938-019-00215-8] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Bergman JJ, Yachimski PS. Advances in Endoscopic Therapy. Gastroenterology 2018;154:1859-60. [PMID: 29653148 DOI: 10.1053/j.gastro.2018.04.007] [Reference Citation Analysis]